Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2022 Earnings Call Transcript

Tony Caggiano: Sure. Yes. Indeed, we’ve been very fortunate to have very significant support from NIA to run biomarker analysis from CSF in all of our studies. So we agree with the importance. Our process right now is really identifying those candidate biomarkers, which will be predictive of change. To answer the question of which ones will take longer and which ones will might be a more acute. We’ll need to look at the data from the more acute studies in order to really tell you which ones will require a longer time. So certainly that is the kind of information we hope to have over the next many months.

Mayank Mamtani: Got it. And sorry, again, if I missed this, did you say what forum you’re looking to present the SEQUEL data? Is there like a conference you’re targeting? And…

Tony Caggiano: We haven’t announced yet. We haven’t announced yet where that will be.

Mayank Mamtani: And a similar question on SHINE. Is there a particular time next year you’re looking to present that data?

Lisa Ricciardi: With SHINE, Mayank, our goal is to complete enrollment this year. The last patient comes in at the end of the year. It’s a six month trial, several months to clean up the data and get top line results. This will really be a function of the enrollment being completed. So we’re saying fall of 2014.

Mayank Mamtani: Understood. Thanks for taking our questions and good luck with all the progress.

Lisa Ricciardi: Thank you, Mayank.

Operator: We have no further questions. I’ll turn the call back over to Cognition’s CEO for closing remarks. Ms. Ricciardi, please go ahead.

Lisa Ricciardi: Thank you. To conclude, I’d like to say that we are optimistic for Cognition’s future and its evolution as we aim to improve the lives of those affected with neurodegenerative diseases. The science is sound and we continue to build evidence about what CT1812 can do for patients. We believe we’re now well positioned to achieve and deliver on multiple clinical milestones and we are focused on creating long term value for our shareholders by doing so. Thank you for joining us this morning and everyone have a great day.

Operator: This concludes today’s conference call. Thank you for your participation. You may now disconnect.